Equity Details
Price & Market Data
Price: $2.01
Daily Change: -$0.0687 / 3.42%
Daily Range: $1.98 - $2.18
Market Cap: $273,162,720
Daily Volume: 595,764
Performance Metrics
1 Week: 5.18%
1 Month: 16.00%
3 Months: -20.39%
6 Months: 47.10%
1 Year: 366.5%
YTD: 79.65%
About ALX Oncology Holdings Inc. (ALXO)
Dive into the latest financial snapshot of ALX Oncology Holdings Inc. (ALXO). With a current trading price of 2.01, the stock has experienced a daily shift of -$0.0687 / 3.42%. The company's market capitalization stands impressively at 273,162,720. Track its year-to-date performance, which is at 79.65%, alongside its weekly, monthly, and yearly trends.
Company Details
Employees: 43
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.